For patients with the rare kidney condition FSGS without nephrotic syndrome, treatment options have been limited. A new approval offers hope. https://t.co/nU4rYdlKr5
🎉🎉🎉Historic day for the #FSGS community— the FDA has fully approved Sparsentan as the first drug for patients with FSGS!! And in addition to adults, it’s approved for children ages 8 and over too 🙌
Special shout out to the #PARASOL ☂️ project that played a pivotal role in defining endpoints for FSGS trials!
So proud to be a part of this amazing community (& former investigator for the DUPLEX trial). And grateful my patients now have a therapy to treat a devastating kidney disease 🙏🏼 @ISGDtweets@nephcure@LauraMarianiMD@ASmith_Stats@mehelmuth@KretzlerM@rheault_m@kirkcampbell
https://t.co/TqsyUVXNui
PARASOL biostats leads Abigail Smith and @mehelmuth gave a guest lecture in @HamiltonCollege BIO 202: Biostatistics class - Nice examples to learn about statistical methods & considerations in longitudinal studies and clinical trials & highlight real life impact of biostats work
✅ Major milestone: FDA confirms proteinuria as an acceptable primary endpoint for full marketing approval of DMX-200 in the US.
A significant step forward for Dimerix and #FSGS patients.
Learn more: https://t.co/n7LwfMhKVb
Just out. Proud to work with these folks from @UMichKidney , @UNCKidney@nationwidekids and @CureGn and @nephcure
“Elevated Exposure To Air Pollutants Accelerates Primary Glomerular Disease Progression”
https://t.co/LSP6MH7TLN
ISGD reunión during the WCN’24:
✅ Members from around the 🌎
✅ GN in ten
✅ Parasol project
✅ Defining MCD and idiopathic nephrotic syndrome
✅ Hot topics in GN session webinar May 10 2024
😊Thank you to everyone who came to this morning's breakfast! Wonderful to meet so many members in person and especially to connect w/ the outstanding neph community here in Argentina and Latin America. We're looking forward to future collaborations! 🎉
-Laurel and Tobias